Alveolar Macrophage Proteomics in HIV-associated Emphysema (HIVE)
This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Alveolar Macrophage Proteomics in HIV-associated Emphysema|
blood lung fluid (optional)
|Study Start Date:||March 2006|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
HIV smokers with emphysema
HIV smokers without emphysema
To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00823927
|United States, Ohio|
|The Ohio State University|
|Columbus, Ohio, United States, 43026|
|Principal Investigator:||Philip T Diaz, MD||Ohio State University|